ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers(AbbVie (United States)), Steven W. Elmore(AbbVie (United States)), Chris Tse(AbbVie (United States)), Sha Jin(AbbVie (United States)), Erwin R. Boghaert(AbbVie (United States)), Darren C. Phillips(AbbVie (United States)), Seong Lin Khaw(Royal Children's Hospital), Xiao Yu(Huazhong Agricultural University), Kennan C. Marsh(AbbVie (United States)), Sari H. Enschede(AbbVie (United States)), Andrew W. Roberts(The Royal Melbourne Hospital), Lloyd T. Lam(National Institutes of Health), Nathaniel D. Catron(AbbVie (United States)), Scott Ackler(AbbVie (United States)), Chang H. Park(AbbVie (United States)), Morey L. Smith(AbbVie (United States)), David C.S. Huang(Indonesia International Institute for Life Sciences), Kylie D. Mason(The Royal Melbourne Hospital), Wayne J. Fairbrother(Gene Therapy Laboratory), Gerard M. Sullivan(AbbVie (United States)), Jackie Lee, Rod Humerickhouse(Abbott Fund), Cheol‐Min Park(AbbVie (United States)), Anatol Oleksijew(Abbott Fund), Deepak Sampath, Brian D. Dayton(AbbVie (United States)), Michael Wendt(Abbott Fund), S.G. Hymowitz, John F. Seymour(The Royal Melbourne Hospital), Heather Maecker, Joel D. Leverson(AbbVie (United States)), Jun Chen(Fourth People's Hospital of Taiyuan), Haichao Zhang(Abbott Fund), Hong Ding(Weill Cornell Medical College in Qatar), Stephen K. Tahir(Abbott Fund), John Xue(AbbVie (United States)), Saul H. Rosenberg(Abbott Fund), Peter Kovar(AbbVie (United States)), Michael J. Mitten(Abbott Fund), Paul Nimmer(Abbott Fund)
Cited by 3,013
Related Papers
Food, nutrition, physical activity, and the prevention of cancer: a global perspective
|Choice Reviews Online|2008|5.4k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k